Scarica l'app Stockscreener
86.00
1.70%
1.44
Dopo l'orario di chiusura:
86.00
Precedente Chiudi:
$84.56
Aprire:
$82.6
Volume 24 ore:
879.70K
Relative Volume:
0.85
Capitalizzazione di mercato:
$4.55B
Reddito:
$2.04M
Utile/perdita netta:
$-162.34M
Rapporto P/E:
-20.91
EPS:
-4.1129
Flusso di cassa netto:
$-129.27M
1 W Prestazione:
+4.31%
1M Prestazione:
+55.63%
6M Prestazione:
+132.87%
1 anno Prestazione:
+381.52%
Intervallo 1D:
$81.81
$87.46
Intervallo di 1 settimana:
$77.64
$88.49
Portata 52W:
$13.37
$88.49
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
86.00 | 4.55B | 2.04M | -162.34M | -129.27M | -4.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Aug Momentum: Can Dianthus Therapeutics Inc expand into new markets2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
A Look At Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains - Sahm
Wedbush keeps outperform on Dianthus Therapeutics, Inc. (DNTH), highlights potential of Claseprubart in CIDP - MSN
Dianthus Therapeutics EVP Sells Over $9 Million in Shares - National Today
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart - finance.yahoo.com
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,492,461.00 in Stock - MarketBeat
Dianthus Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Wells Fargo Remains a Buy on Dianthus Therapeutics (DNTH) - The Globe and Mail
Dianthus Therapeutics(DNTH.US) Officer Sells US$9.49 Million in Common Stock - Moomoo
Dianthus Therapeutics stock hits 52-week high at 88.35 USD By Investing.com - Investing.com Australia
Dianthus therapeutics director Soteropoulos sells $47985 in stock By Investing.com - Investing.com Canada
Dianthus therapeutics director Soteropoulos sells $47985 in stock - Investing.com
Savitz of Dianthus sold $9.5m in DNTH stock - Investing.com UK
Savitz of Dianthus sold $9.5m in DNTH stock By Investing.com - Investing.com Canada
Dianthus Therapeutics Insider Sold Shares Worth $9,492,596, According to a Recent SEC Filing - MarketScreener
Dianthus Therapeutics (DNTH) CFO exercises options, sells 114,367 shares - Stock Titan
Dianthus Therapeutics (DNTH) director exercises options then sells 599 shares - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 88.35 USD - Investing.com
Dianthus rises as FDA agrees with proposed changes to lead program - MSN
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
DNTH insider sells 27,594 shares via 10b5-1; plans 1,198-share option sale (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH) Receives a Buy from Wells Fargo - The Globe and Mail
Dianthus Therapeutics (DNTH) price target increased by 70.00% to 130.48 - MSN
Dianthus Therapeutics, Inc. Insider Sold Shares Worth $2,153,712, According to a Recent SEC Filing - MarketScreener
Dianthus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Soteropoulos Paula - Moomoo
Dianthus Therapeutics Advances Claseprubart and DNTH212 as Potential Best-in-Class Autoimmune Therapies with Pipeline-in-a-Product Potential and Strong Clinical Data - minichart.com.sg
Director at Dianthus Therapeutics (DNTH) exercises options and sells shares - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.6%Time to Buy? - marketbeat.com
Dianthus says FDA agrees with changes to lead program (DNTH) - Seeking Alpha
According to a public SEC filing, biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) is adjusting the enrollment criteria for the clinical trial of its core drug Claseprubart. - Bitget
FDA backs Dianthus (NASDAQ: DNTH) lupus risk update as cash runway extends to 2030 - Stock Titan
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - AOL.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) reports Q4 loss, misses revenue estimates - MSN
Dianthus Therapeutics, Inc. (DNTH) stock jumps 12.0%: Will it continue to soar? - MSN
Assessing Dianthus Therapeutics (DNTH) Valuation After CAPTIVATE Milestone And Upsized Equity Offering - simplywall.st
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on? - MSN
Wells Fargo Initiates Coverage on Dianthus Therapeutics - National Today
Wells Fargo & Company Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Wells Fargo Initiates Dianthus Therapeutics at Overweight - marketscreener.com
Wells Fargo reiterates Dianthus Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) - MSN
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP - Insider Monkey
Biotech shares soar by 288% following a major funding round, with an early investor disclosing a $14 million cash-out - Bitget
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):